Shin Nippon Biomedical Laboratories Ltd operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shin Nippon Biomedical Laboratories Ltd with three other
miscellaneous service companies in Asia:
Morishita Jintan Co., Ltd.
sales of 9.77 billion Japanese Yen [US$93.15 million]
of which 75%
was Health Care Business),
Vimta Labs Limited
(1.81 billion Indian Rupees [US$24.58 million]
of which 100%
was contract research and testing services), and
Linical Company Limited
(10.94 billion Japanese Yen [US$104.21 million]
of which 91%
was Cro Business).
During the year ended March of 2020, sales at
Shin Nippon Biomedical Laboratories Ltd were ¥14.56 billion (US$138.77 million).
decrease of 7.0%
versus 2019, when the company's sales were ¥15.66 billion.
Contributing to the drop in overall sales was the 89.6% decline
in Translational Research Project, from ¥11.54 million to ¥1.20 million.
There were also decreases in sales in
Pre-Clinical Business (down 4.6% to ¥13.08 billion)
Clinical Business (down 53.7% to ¥453.98 million)
However, these declines were partially offset by the increase in sales of
Police Medi (up 3.6% to ¥964.48 million)
Other (up 228.8% to ¥56.98 million)